Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.

Gulbanu SarsenbayevaYevgeniy VolginMarkhabat KassenovTimur IssagulovNikolay BogdanovAbylay SansyzbayMarina StukovaZhanna BuzitskayaIlyas КulmagambetovTimur DavlyatshinBerik Khairullin

Published in: Human vaccines & immunotherapeutics (2017)

Comparison of the allantoic inactivated split vaccine obtained in vaccines RIBSP and VAXIGRIP®, showed similar immunogenic activity. Both vaccines were safe for the study participants.

Keyphrases

phase ii
clinical trial
open label
double blind
phase iii
placebo controlled
study protocol
randomized controlled trial